AU Patent

AU2024261630A1 — Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome

Assigned to Viela Bio Inc · Expires 2025-09-04 · 1y expired

What this patent protects

Provided are compositions and methods comprising a CD40L-specific Tn3 scaffold. Also provided are methods of utilizing the same for the prevention and treatment of Sjögren's Syndrome.

USPTO Abstract

Provided are compositions and methods comprising a CD40L-specific Tn3 scaffold. Also provided are methods of utilizing the same for the prevention and treatment of Sjögren's Syndrome.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024261630A1
Jurisdiction
AU
Classification
—
Expires
2025-09-04
Drug substance claim
No
Drug product claim
No
Assignee
Viela Bio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.